Skip to main content

Advertisement

SpringerLink
Log in

An interaction between the inflammatory condition and the hypercoagulable condition occurs in primary Sjögren syndrome

  • BRIEF REPORT
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

This study aimed to assess the d-dimer level in patients with primary Sjögren syndrome (pSS), uncover its relationship with clinical symptoms, and appraise its predictive value in discriminating disease activity. The laboratory parameters of 101 consecutive patients with pSS and 101 healthy controls were analyzed and compared. Patients were divided into two subgroups according to their d-dimer levels, for the comparison of clinical features. Pearson’s correlations were used to measure the relationships between d-dimer levels and other variables. The area under the curve (AUC) was calculated to predict disease activity. The erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hsCRP) level, and d-dimer level were each higher in patients with pSS than in healthy controls. Compared with the low-d-dimer-level patients, those with elevated d-dimer levels exhibited higher ESRs (p < 0.0001) and higher levels of hsCRP (p < 0.0001), fibrinogen (p < 0.0001), and immunoglobulin A (p = 0.002). Cases with elevated d-dimer levels were prone to be more severe, based on ESSDAI evaluation (p < 0.0001). Patients with higher d-dimer levels had more articular involvement (p < 0.0001), which was significantly correlated with both the ESR (r = 0.21, p = 0.03) and hsCRP level (r = 0.56, p = 0.001). The d-dimer level may help to discriminate low disease activity from moderate/high disease activity (AUC = 0.754). The d-dimer level was correlated positively with both the ESR and hsCRP level in patients with pSS. The ESR and levels of hsCRP, fibrinogen, and disease activity were higher in the elevated d-dimer level group. The d-dimer level was demonstrated to have predictive value in differentiating pSS disease activity.

Key Points

•D-Dimer was higher in patients with pSS.

•D-Dimer may help for predicting the disease activity in patients with pSS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Fox RI (2005) Sjögren’s syndrome. Lancet 366(9482):321–331

    Article  CAS  PubMed  Google Scholar 

  2. Bombardieri M, Argyropoulou OD, Ferro F et al (2020) One year in review 2020: pathogenesis of primary Sjögren’s syndrome. Clin Exp Rheumatol 38 Suppl 126(4):3–9

    PubMed  Google Scholar 

  3. Roescher N, Tak PP, Illei GG (2009) Cytokines in Sjögren’s syndrome. Oral Dis 15(8):519–526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Marzano AV, Tedeschi A, Polloni I, Crosti C, Cugno M (2012) Interactions between inflammation and coagulation in autoimmune and immune-mediated skin diseases. Curr Vasc Pharmacol 10(5):647–652

    Article  CAS  PubMed  Google Scholar 

  5. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ (2011) Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 9:1

    Article  PubMed  PubMed Central  Google Scholar 

  6. Wu H, Birmingham DJ, Rovin B et al (2008) D-Dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol 3(6):1628–1636

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Xue L, Tao L, Li X et al (2021) Plasma fibrinogen, D-dimer, and fibrin degradation product as biomarkers of rheumatoid arthritis. Sci Rep 11(1):16903

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 69(1):35–45

    Article  PubMed  Google Scholar 

  9. Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis 69(6):1103–1109

    Article  PubMed  Google Scholar 

  10. Seror R, Bootsma H, Saraux A et al (2016) Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75(2):382–389

    Article  CAS  PubMed  Google Scholar 

  11. Weitz JI, Fredenburgh JC, Eikelboom JW (2017) A test in context: D-dimer. J Am Coll Cardiol 70(19):2411–2420

    Article  CAS  PubMed  Google Scholar 

  12. Cicarini WB, Duarte RCF, Ferreira KS et al (2020) Impact of markers of endothelial injury and hypercoagulability on systemic lupus erythematosus. Lupus 29(2):182–190

    Article  PubMed  Google Scholar 

  13. Aviña-Zubieta JA, Jansz M, Sayre EC, Choi HK (2017) The risk of deep venous thrombosis and pulmonary embolism in primary Sjögren syndrome: a general population-based study. J Rheumatol 44(8):1184–1189

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medcine, 600 Yishan Road, 200233, Shanghai, China

    Qian Wang & Sheng-Ming Dai

Authors
  1. Qian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheng-Ming Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheng-Ming Dai.

Ethics declarations

Disclosures

None.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Q., Dai, SM. An interaction between the inflammatory condition and the hypercoagulable condition occurs in primary Sjögren syndrome. Clin Rheumatol 42, 1107–1112 (2023). https://doi.org/10.1007/s10067-022-06498-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-022-06498-0

Keywords

Search

Navigation